Full Text | PDF

Share on tweeters Share on facebook Share on linkedin Share on googleplus

Int J Med Sci 2023; 20(13):1698-1704. doi:10.7150/ijms.89242 This issue Cite

Research Paper

Use of metagenomic next-generation sequencing for diagnosis of peritonitis in end-stage liver disease

Taiyu He*, Ning Luo*, Juan Kang, Ning Ling, Dazhi Zhang✉

Department of Infectious Diseases, Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, the Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.
*These authors contributed equally to this work

✉ Corresponding author: Dazhi Zhang. Address: Department of Infectious Diseases, Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, the Second Affiliated Hospital, Chongqing Medical Univ More

Citation:
He T, Luo N, Kang J, Ling N, Zhang D. Use of metagenomic next-generation sequencing for diagnosis of peritonitis in end-stage liver disease. Int J Med Sci 2023; 20(13):1698-1704. doi:10.7150/ijms.89242. https://www.medsci.org/v20p1698.htm
Other styles

File import instruction

Abstract

Graphic abstract

Background: Conventional methods are low in positive rates and time-consuming for ascites pathogen detection in patients with end-stage liver disease (ESLD). With many advantages, metagenomic next-generation sequencing (mNGS) may be a good alternative method. However, the related studies are still lacking.

Methods: Ascites from 50 ESLD patients were sampled for pathogen detection using mNGS and conventional methods (culture and polymorphonuclear neutrophils detection) in this prospective observational study.

Results: Forty-two samples were detected positive using mNGS. 29 strains of bacteria, 11 strains of fungi, and 9 strains of viruses were detected. 46% of patients were detected to be co-infected with 2 or more pathogens by mNGS. Moreover, mNGS showed similar and high positive rates in ESLD patients with different clinical characteristics. Compared to conventional methods, mNGS had higher positivity rates (84% vs. 20%, P<0.001), sensitivity (45.2% vs. 23.8%, P=0.039), broader pathogen spectrum, shorter detection time (24 hours vs. 3-7 days), but lower specificity (25% vs 100%, P = 0.010). Furthermore, compared to conventional methods, mNGS showed similar consistence with final diagnosis (42% vs. 36%, P=0.539).

Conclusions: mNGS may be a good supplement for conventional methods and helpful to early etiological diagnosis of peritonitis, and thus improve ESLD patients' survival.

Keywords: Metagenomic next-generation sequencing, conventional methods, peritonitis, end-stage liver disease, diagnosis

Citation styles

APA
He, T., Luo, N., Kang, J., Ling, N., Zhang, D. (2023). Use of metagenomic next-generation sequencing for diagnosis of peritonitis in end-stage liver disease. International Journal of Medical Sciences, 20(13), 1698-1704. https://doi.org/10.7150/ijms.89242.

ACS
He, T.; Luo, N.; Kang, J.; Ling, N.; Zhang, D. Use of metagenomic next-generation sequencing for diagnosis of peritonitis in end-stage liver disease. Int. J. Med. Sci. 2023, 20 (13), 1698-1704. DOI: 10.7150/ijms.89242.

NLM
He T, Luo N, Kang J, Ling N, Zhang D. Use of metagenomic next-generation sequencing for diagnosis of peritonitis in end-stage liver disease. Int J Med Sci 2023; 20(13):1698-1704. doi:10.7150/ijms.89242. https://www.medsci.org/v20p1698.htm

CSE
He T, Luo N, Kang J, Ling N, Zhang D. 2023. Use of metagenomic next-generation sequencing for diagnosis of peritonitis in end-stage liver disease. Int J Med Sci. 20(13):1698-1704.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2024 Ivyspring International Publisher. Terms of use